BenevolentTech

BenevolentAI is a clinical-stage AI-enabled drug discovery company that integrates artificial intelligence with scientific expertise to discover and develop novel medicines for complex diseases. The company utilizes its proprietary 'Benevolent Platform' to analyze vast amounts of multimodal biomedical data, identifying novel drug targets and developing a pipeline of high-value assets. Its lead programs include BEN-8744, a PDE10 inhibitor for ulcerative colitis, and BEN-28010, a CHK1 inhibitor for glioblastoma. BenevolentAI maintains significant strategic partnerships with major pharmaceutical companies like AstraZeneca and Merck KGaA to accelerate drug discovery across various therapeutic areas. In March 2025, the company underwent a corporate restructuring, merging into Osaka Holdings and delisting from the Euronext Amsterdam exchange to continue operations as a private entity.